Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SONAR trial of atrasentan in type 2 diabetic nephropathy
2012-005848-21Phase 3Terminated
- Sponsor
- AbbVie Inc.
- Start
- Sep 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diabetic glomerulosclerosis comparing Atrasentan with Placebo (2 arms). Primary endpoint: Primary composite renal endpoint. Started Sep 2013; status: terminated.
02
Drugs
atrasentan
03
Conditions
diabetic glomerulosclerosis
Beyond the preview
Go deeper on 2012-005848-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-005848-21.